Kayne Anderson Rudnick Investment Management
EPZM

Kayne Anderson Rudnick Investment Management’s Epizyme, Inc EPZM Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,000
Closed -$47K – 652
2020
Q1 		$47K Buy
+3,000
New +$64.4K ﹤0.01% 395

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's EPZM Position: Q2 2020 in Review

Kayne Anderson Rudnick Investment Management sold out of Epizyme, Inc (EPZM) in Q2 2020, closing a stake of 3,000 shares — an estimated $47K sold.

Kayne Anderson Rudnick Investment Management first reported a position in EPZM in Q1 2020 and held it in 1 quarter. The position peaked at $47K in Q1 2020. 160 funds tracked by Wall St. Rank hold EPZM as of Q2 2020.

  • Kayne Anderson Rudnick Investment Management reported no remaining Epizyme, Inc position as of Q2 2020 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 3,000 Epizyme, Inc shares in Q2 2020, an estimated $47K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Epizyme, Inc in Q1 2020 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Epizyme, Inc position peaked at $47K in Q1 2020.
  • 160 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2020.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.